Cannabis MarketSize, Share & Industry Analysis, 2026-2034By SourceBy DerivativeBy End-useBy Depression and AnxietyBy Distribution Channel
Full title & scope — all 5 axes with their segments
Cannabis Market Size, Share & Industry Analysis, By Source (Marijuana, Flowers, Oil and Tinctures, Hemp, Hemp CBD, Supplements, Industrial Hemp), By Derivative (THC, CBD, Others), By End-use (Medical Use, Cancer, Chronic Pain), By Depression and Anxiety (Recreational Use, Industrial Use, Epilepsy, Multiple Sclerosis, Arthritis, Post-Traumatic Stress Disorder, Migraines, Glaucoma, Parkinson's, Diabetes, Alzheimer's, AIDS, Amyotrophic Lateral Sclerosis, Tourette's), By Distribution Channel (Dispensaries and Retail Stores, Pharmacies, Online and E-commerce), and Regional Forecast, 2026-2034
How the estimates were built: data sources, modelling approach and validation steps.
- 01By SourceMarijuana · Flowers · Oil and Tinctures
- 02By DerivativeTHC · CBD · Others
- 03By End-useMedical Use · Cancer · Chronic Pain
- 04By Depression and AnxietyRecreational Use · Industrial Use · Epilepsy
- 05By Distribution ChannelDispensaries and Retail Stores · Pharmacies · Online and E-commerce
- 06By Region
Market Analysis & Outlook
The cannabis market covers legally cultivated and processed cannabis and hemp-derived products sold for medical, wellness and adult recreational use, spanning raw flower, oils, tinctures, concentrates, edibles, topicals and hemp-derived CBD formulations. Buyers range from licensed dispensaries, pharmacies and specialty retailers to individual medical patients under physician-supervised programs and adult consumers in jurisdictions permitting recreational sale. It excludes cannabis grown or sold outside a jurisdiction's licensed legal framework.
The global cannabis market stood at USD 68 billion in 2025. A forecast-period rate of 12.18% takes it to USD 194.3 billion by 2034, and the study reports every year in between, passing USD 31.5 billion in 2020, USD 58.8 billion in 2024, USD 77.5 billion in 2026 and USD 125.7 billion in 2030.
On the source axis, growth rates run from 10.35% for Flowers up to 15.77% for Industrial Hemp. Marijuana carries the volume: USD 23.12 billion and 34% of revenue in 2025, USD 60.23 billion and 31% in 2034. The lines gaining share are Oil and Tinctures, Hemp CBD, Supplements and Industrial Hemp. Marijuana, Flowers and Hemp lose share without losing revenue.
Cut by derivative, the largest line is THC: 58% of 2025 revenue, worth USD 39.44 billion, and 52% at USD 101.04 billion by 2034. Others grows faster at 14.68% against 11.02%, moving from 5% of revenue to 6% by 2034. Both this axis and the source one divide the same revenue, which is why they are alternative views rather than components.
Geographically, 62% of 2025 revenue sits in North America (USD 42.16 billion rising to USD 106.87 billion) ahead of Europe at 20% and USD 13.6 billion. Middle East and Africa is smallest, at 3%. Share shifts toward Europe and Asia Pacific over the forecast period, which is what makes the regional split worth reading rather than assuming.
Coverage extends to five regions, seven source lines and five segmentation axes over the full fifteen years. The 2025 total itself is triangulated from published sources and category proxies rather than an independently sourced count, and the splits below are estimated on that same basis, a bound on their precision worth carrying into any use of them.
Market Size, 2020–2034
USD BillionRevenue in USD Billion. Values up to 2025 are actuals; 2026–2034 are forecast.
Key Takeaways
- A forecast-period rate of 12.18% takes the market from USD 68 billion in 2025 to USD 194.3 billion in 2034, against 16.65% recorded over the 2020-2025 historical period.
- Marijuana is the largest source line at USD 23.12 billion in 2025, a 34% share, reaching USD 60.23 billion and 31% of revenue by 2034.
- Industrial Hemp is the fastest-growing line at 15.77%, lifting its share from 3% in 2025 to 4% in 2034 and its revenue from USD 2.04 billion to USD 7.77 billion.
- The bull case puts 2034 revenue at USD 223.45 billion and the bear case at USD 169.04 billion, either side of the USD 194.3 billion base case, each with its own stated assumption in the full report.
- North America holds 62% of global revenue in 2025 at USD 42.16 billion, the largest of the five regions tracked, and reaches USD 106.87 billion by 2034.
- Within North America, the United States is the worked country example, at USD 34.99 billion in 2025; 83% of regional revenue in the base year, and USD 85.5 billion by 2034.
- The study covers 2020 through 2034 with 2025 as the base year, reporting five regions and five segmentation axes separately, with revenue, share and a growth rate for every line in each year.
Market Trends
Revenue Share, By By Source
Base year 2025Marijuana leads with 34.0% of by source segment revenue.
Share of by source segment revenue, most recent base year. The 1 smallest segments are grouped as Other.
Three movements define the forecast period in the global cannabis market: how the source mix changes, where regional weight shifts, and the rate at which the total compounds.
All three are changes in mix rather than in direction: nothing contracts, and the movement is in which lines and regions absorb the new revenue.
Industrial Hemp grows faster than Flowers. 15.77% against 10.35%: that gap, between Industrial Hemp and Flowers, is the largest on the source axis. Over the forecast period that moves Industrial Hemp from 3% of revenue to 4%, and Flowers from 22% to 19%. In absolute terms Industrial Hemp rises from USD 2.04 billion to USD 7.77 billion, while Flowers rises from USD 14.96 billion to USD 36.92 billion. Both grow; the gap is wide enough to reshape the mix inside a single forecast window.
Regional weight shifts toward Europe and Asia Pacific. Europe moves from 20% of revenue in 2025 to 24% in 2034, worth USD 13.6 billion rising to USD 46.63 billion; Asia Pacific moves from 9% of revenue in 2025 to 12% in 2034, worth USD 6.12 billion rising to USD 23.32 billion. Share moves off the others in turn: North America at 62% moving to 55%, Latin America at 6% moving to 6%, Middle East and Africa at 3% moving to 3%, each still growing in revenue terms. Growth is therefore not something a participant inherits from the market; it depends on which regions its revenue is weighted toward.
Growth compounds at 12.18% without a step change. Fifteen years of revenue run USD 31.5 billion in 2020, USD 58.8 billion in 2024, USD 68 billion in 2025, USD 77.5 billion in 2026, USD 125.7 billion in 2030 and USD 194.3 billion in 2034. The forecast rate of 12.18% sits against 16.65% over the historical period, so the projection extends an observed trend instead of proposing a new one. A plan built on this market is therefore a plan about capturing a share of steady expansion, which is decided on the source and regional axes, not by the headline rate.
Market Growth Factors
The fastest line decides the blended rate
Market Drivers
3- 01The fastest line decides the blended rate
15.77% growth in Industrial Hemp, against 12.18% for the market as a whole, moves it from USD 2.04 billion and 3% of revenue in 2025 to USD 7.77 billion and 4% in 2034. Because the spread to Flowers at 10.35% is this wide, the headline 12.18% is a weighted result rather than a rate any single line achieves. That makes position on the source axis a growth decision rather than a product one.
- 02The two largest regions hold most of the base
62% of 2025 revenue (USD 42.16 billion) is generated in North America, reaching USD 106.87 billion by 2034 at an unchanged 55%. Europe adds a further 20% at USD 13.6 billion, reaching USD 46.63 billion. Because both the existing revenue and the revenue added concentrate in these two, regional weighting matters more to a forecast than regional count does.
- 03A demonstrated trajectory, not a projected turnaround
The historical period compounded at 16.65%; USD 31.5 billion in 2020, USD 58.8 billion in 2024 and USD 68 billion in 2025. The forecast period then runs at 12.18%, ending 2034 at USD 194.3 billion. A forecast extending an observed trend is a different proposition from one proposing a turn, and that is why no ramp is applied: the 12.18% runs evenly across the period.
Growth drivers
| # | Growth driver | Impact | Gross contribution (Billion) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | Expanding adult-use legalization across new state and national markets | High | +42 | High | High | Medium |
| 2 | Broader medical cannabis prescribing and reimbursement pathways | High | +28 | Medium | High | High |
| 3 | Wellness and CBD product entry into general retail and e-commerce | Medium-High | +22 | High | Medium | Medium |
| 4 | Rising cultivation efficiency lowering per-unit production costs | Medium | +16 | Medium | Medium | High |
| 5 | Opening international trade corridors between licensed-producer countries | Medium | +12 | Low | Medium | High |
| 6 | Others | Low | +24.3 | Low | Low | Low |
| Total | +144.3 | |||||
Restraints
| # | Restraint | Impact | Estimated reduction (Billion) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | Continued federal illegality in the United States restricting banking and interstate commerce | High | −9 | High | Medium | Low |
| 2 | Price compression in mature adult-use markets as supply outpaces demand | Medium | −5 | Medium | High | Medium |
| 3 | Slow and fragmented licensing across European Union member states | Medium | −4 | Medium | Medium | Low |
| Total | −18 | |||||
Drivers contribute 144.3 Billion and restraints remove 18 Billion, a net 126.3 Billion, which is the revenue the market adds between the base year and 2034. Contributions are CDI estimates, apportioned so that they reconcile with the forecast rather than being read from it.
The 12.18% forecast rate rests on three things that can be measured separately: the size of the existing base, the mix shift on the source axis, and where regional growth is concentrated.
Restraining Factors
The bear case and what drives it
Market Restraints
2- 01The bear case and what drives it
Where the forecast could miss: bear assumes U.S. federal reform stalls beyond 2028, cultivation oversupply extends price compression further into the forecast period, and at least one currently-legal European medical market tightens its licensing framework. That path reaches USD 169.04 billion by 2034 instead of USD 194.3 billion, off an unchanged USD 68 billion in 2025.
- 02The largest line is not the fastest
Marijuana carries 34% of 2025 revenue at USD 23.12 billion but compounds at 11.01% against 12.18% for the market, taking its share to 31% by 2034 even as revenue rises to USD 60.23 billion. Because it carries that much of the base, its pace holds the blended rate down more than any faster line lifts it.
Market Opportunities
Where the forecast could be beaten
Market Opportunities
2- 01Where the forecast could be beaten
Bull assumes faster-than-scheduled legalization in additional U.S. states and at least one major EU market beyond Germany, plus continued double-digit growth in CBD wellness retail without a price-compression correction. On that assumption the market reaches USD 223.45 billion by 2034 rather than USD 194.3 billion, from the same USD 68 billion in 2025.
- 02The opening is on the source axis, not the regional one
Industrial Hemp grows at 15.77% against 12.18% for the market, adding revenue from USD 2.04 billion in 2025 to USD 7.77 billion in 2034 and taking its share from 3% to 4%. It is the place on this axis where share changes hands at scale, so it is where an entrant can take position without displacing the incumbent in Marijuana.
Market Challenges
Concentration on the source axis
Market Challenges
2- 01Concentration on the source axis
USD 23.12 billion of 2025 revenue sits in Marijuana, 34% of the total, and it is still 31% at USD 60.23 billion nine years later. That concentration means the market's own forecast is, to a large extent, a forecast for one source line.
- 02The United States is 83% of North America
83% of the leading region is one country: the United States, at USD 34.99 billion against North America's USD 42.16 billion in 2025, and USD 85.5 billion by 2034. The consequence is that regional risk here is really country risk wearing a larger label.
Segmentation Analysis
5 axesThe market is divided by source and by derivative, end-use, depression and anxiety and distribution channel; five axes in all. They are alternative readings of one revenue pool, not parts that sum to it.
All seven source lines expand in revenue terms over the forecast period. Share is the dividing line; four take it, the others cede it.
By Source · 7 segments
By Source
- Largest Marijuana · 34%
- Fastest Industrial Hemp · 15.8%
- Moves most Marijuana · -3 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Marijuana | $23.12B | 34% | $60.23B | 31%-3 | 11% |
| Flowers | $14.96B | 22% | $36.92B | 19%-3 | 10.3% |
| Oil and Tinctures | $9.52B | 14% | $31.09B | 16%+2 | 13.8% |
| Hemp | $6.80B | 10% | $17.49B | 9%-1 | 10.9% |
| Hemp CBD | $8.16B | 12% | $29.15B | 15%+3 | 15% |
| Supplements | $3.40B | 5% | $11.66B | 6%+1 | 14.4% |
| Industrial Hemp | $2.04B | 3% | $7.77B | 4%+1 | 15.8% |
2025 to 2034 revenue and share by line: Marijuana USD 23.12 billion to USD 60.23 billion (34% to 31%), Flowers USD 14.96 billion to USD 36.92 billion (22% to 19%), Oil and Tinctures USD 9.52 billion to USD 31.09 billion (14% to 16%), Hemp CBD USD 8.16 billion to USD 29.15 billion (12% to 15%), Hemp USD 6.8 billion to USD 17.49 billion (10% to 9%), Supplements USD 3.4 billion to USD 11.66 billion (5% to 6%), Industrial Hemp USD 2.04 billion to USD 7.77 billion (3% to 4%). Industrial Hemp Outpaces the Axis While Marijuana Holds the Largest Share Marijuana and flower products lead this axis because they still carry the broadest distribution footprint across dispensaries and retail stores built up since early legalization. Hemp CBD grows fastest as wellness-oriented, non-intoxicating formats expand into general retail, pharmacy and online channels that carry none of the age-gated restrictions flower and marijuana products face. The order does not change: Marijuana is still largest in 2034, and what moves is how much it holds. This is the axis the estimation prices in full, year by year, and the one the regional chapters cut against.
By Derivative · 3 segments
Scale in THC and Growth in Others Define the Derivative Axis
- Largest THC · 58%
- Fastest Others · 14.7%
- Moves most THC · -6 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| THC | $39.44B | 58% | $101B | 52%-6 | 11% |
| CBD | $25.16B | 37% | $81.61B | 42%+5 | 14% |
| Others | $3.40B | 5% | $11.66B | 6%+1 | 14.7% |
THC-led products remain the largest derivative category because psychoactive potency continues to anchor recreational and high-need medical purchases in mature legal markets. CBD and other non-intoxicating derivatives grow fastest as wellness, topical and functional-food formats reach shoppers through general retail and online channels that carry no age-gated dispensary requirement. The order does not change: THC is still largest in 2034, and what moves is how much it holds.
By End-use · 3 segments
Medical Use Held the Dominant Share of the End-use Segment in 2025
- Largest Medical Use · 55%
- Fastest Chronic Pain · 13.8%
- Moves most Medical Use · -5 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Medical Use | $37.40B | 55% | $97.15B | 50%-5 | 11.2% |
| Cancer | $13.60B | 20% | $42.75B | 22%+2 | 13.6% |
| Chronic Pain | $17B | 25% | $54.40B | 28%+3 | 13.8% |
Medical Use leads because broad-indication clinical adoption already covers the largest patient population, while Chronic Pain grows fastest as opioid-sparing treatment protocols and an aging population widen the number of prescribers willing to recommend cannabis-based therapy ahead of other indications. Medical Use remains the largest line through 2034, so the axis changes in proportion rather than in order.
By Depression and Anxiety · 14 segments
By Depression and Anxiety
- Largest Recreational Use · 44%
- Fastest Industrial Use · 15.2%
- Moves most Recreational Use · -3 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Recreational Use | $29.92B | 44% | $79.66B | 41%-3 | 11.5% |
| Industrial Use | $2.72B | 4% | $9.72B | 5%+1 | 15.2% |
| Epilepsy | $5.44B | 8% | $17.49B | 9%+1 | 13.9% |
| Multiple Sclerosis | $4.76B | 7% | $14.57B | 7.5%+0.5 | 13.2% |
| Arthritis | $4.08B | 6% | $12.63B | 6.5%+0.5 | 13.4% |
| Post-Traumatic Stress Disorder (PTSD) | $4.08B | 6% | $12.63B | 6.5%+0.5 | 13.4% |
| Migraines | $3.40B | 5% | $9.72B | 5% | 12.4% |
| Glaucoma | $2.72B | 4% | $7.77B | 4% | 12.4% |
| Parkinson's | $2.72B | 4% | $7.77B | 4% | 12.4% |
| Diabetes | $2.04B | 3% | $5.83B | 3% | 12.4% |
| Alzheimer's | $2.04B | 3% | $5.83B | 3% | 12.4% |
| AIDS | $2.04B | 3% | $4.86B | 2.5%-0.5 | 10.1% |
| Amyotrophic Lateral Sclerosis | $1.36B | 2% | $3.89B | 2% | 12.4% |
| Tourette's | $0.68B | 1% | $1.94B | 1% | 12.3% |
2025 to 2034 revenue and share by line: Recreational Use USD 29.92 billion to USD 79.66 billion (44% in 2025), Epilepsy USD 5.44 billion to USD 17.49 billion (8% in 2025), Multiple Sclerosis USD 4.76 billion to USD 14.57 billion (7% in 2025), Arthritis USD 4.08 billion to USD 12.63 billion (6% in 2025), Post-Traumatic Stress Disorder (PTSD) USD 4.08 billion to USD 12.63 billion (6% in 2025), Migraines USD 3.4 billion to USD 9.72 billion (5% in 2025), Industrial Use USD 2.72 billion to USD 9.72 billion (4% in 2025), Glaucoma USD 2.72 billion to USD 7.77 billion (4% in 2025), Parkinson's USD 2.72 billion to USD 7.77 billion (4% in 2025), Diabetes USD 2.04 billion to USD 5.83 billion (3% in 2025), Alzheimer's USD 2.04 billion to USD 5.83 billion (3% in 2025), AIDS USD 2.04 billion to USD 4.86 billion (3% in 2025), Amyotrophic Lateral Sclerosis USD 1.36 billion to USD 3.89 billion (2% in 2025), Tourette's USD 0.68 billion to USD 1.94 billion (1% in 2025). Scale in Recreational Use and Growth in Industrial Use Define the Depression and anxiety Axis Recreational Use remains the largest line because adult-use retail volume across legal jurisdictions still exceeds the patient base of any single clinical indication. Industrial Use grows fastest as non-intoxicating hemp derivatives find expanding roles in materials, textiles and manufacturing inputs outside the medical and recreational retail channel entirely. By 2034 Recreational Use is still ahead, making this a shift in weight rather than a change of leader.
By Distribution Channel · 3 segments
Online and E-commerce Outpaces the Axis While Dispensaries and Retail Stores Holds the Largest Share
- Largest Dispensaries and Retail Stores · 68%
- Fastest Online and E-commerce · 17.3%
- Moves most Dispensaries and Retail Stores · -8 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Dispensaries and Retail Stores | $46.24B | 68% | $117B | 60%-8 | 10.8% |
| Pharmacies | $11.56B | 17% | $34.97B | 18%+1 | 13.1% |
| Online and E-commerce | $10.20B | 15% | $42.75B | 22%+7 | 17.3% |
Dispensaries and specialty retail stores lead distribution because most jurisdictions still license cannabis sale through dedicated storefronts rather than general retail. Online and e-commerce grows fastest as delivery-permitted markets mature and consumers who already know the product they want shift routine reorders away from in-person visits. The order does not change: Dispensaries and Retail Stores is still largest in 2034, and what moves is how much it holds.
Regional Insights
Regional Revenue Share
Base year 2025Share of global revenue in the base year.
Only the leading region's share is published outside the report; pins mark the region, not a specific country.
North America Market Analysis
The largest region covered, and the one giving up the most — 7 points of share move elsewhere by 2034, while revenue still grows 2.5×.
- Rank 1 of 5
- 2025 share 62%
- By 2034 55%
- Revenue $42.16B → $107B
In North America, 62% of global revenue puts 2025 at USD 42.16 billion on the way to USD 106.87 billion by 2034. By revenue it sits first across the study, and the ranking does not change between 2025 and 2034.
Its share moves to 55% by 2034, a shift in share rather than in direction: revenue climbs every year while the market's centre of gravity moves elsewhere.
The source mix reported at global level applies here, with Marijuana the largest line at 34% of 2025 revenue and Industrial Hemp the fastest-growing at 15.77%. The full report breaks North America out along every axis and by country.
United States
Sets the pace for North America at 83% of it, growing 2.4×.
- In region 1 of 2
- Of region 83%
- Of global 51.5%
- Revenue $34.99B → $85.50B
The largest single market in North America is the United States, at USD 34.99 billion in 2025 and USD 85.5 billion in 2034. At 83% of regional revenue in the base year it is not one market among several, the region's trajectory is largely this country's trajectory. Regional revenue of USD 42.16 billion in 2025 and USD 106.87 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.
Demand in the United States follows the source mix reported at global level: Marijuana is the largest line at 34% of 2025 revenue, moving to 31% by 2034, while Industrial Hemp grows fastest at 15.77% and takes its share from 3% to 4%. Its 83% weight in North America means those movements carry straight into the regional totals. Per-source revenue for the United States appears on its own in the full report.
Cannabis remains federally controlled substance regulated by the Drug Enforcement Administration, which classifies it under the Controlled Substances Act as a substance with no accepted medical use at the federal level, while individual states operate their own licensing and testing regimes for cultivation, processing, and retail sale. Suppliers operating in legal state markets must obtain state-level cultivation, manufacturing, and dispensary licenses, comply with seed-to-sale tracking requirements, and meet state-mandated potency testing, contaminant screening, and child-resistant packaging and labelling standards. Hemp-derived products with minimal intoxicating compound content fall instead under United States Department of Agriculture oversight for cultivation and Food and Drug Administration authority over food, supplement, and cosmetic claims, creating a fragmented compliance landscape suppliers must navigate market by market.
Competition in the United States runs between the suppliers this study tracks: Canopy Growth Corporation, GW Pharmaceuticals, plc, Aurora Cannabis, Inc., Aphria, Inc., Cronos Group, Tilray, Sundial Growers Inc., Insys Therapeutics, Inc., The Scotts Company LLC, VIVO Cannabis Inc., Cara Therapeutics Inc., Curaleaf Holdings, Inc., Trulieve Cannabis Corp., Green Thumb Industries Inc. and Verano Holdings Corp.. The commercially relevant division is 34% of 2025 revenue in Marijuana, where the volume is, against 15.77% growth in Industrial Hemp, where share moves. Per-company positioning and share at country level are in the full report only.
Canada
2nd-largest in North America, growing 3.0×.
- In region 2 of 2
- Of region 17%
- Of global 10.5%
- Revenue $7.17B → $21.37B
10.54% of global revenue is generated in Canada; USD 7.17 billion in 2025, reaching USD 21.37 billion in 2034, and 17% of North America.
Europe Market Analysis
The 2nd-largest region covered — it picks up 4 points of share by 2034, while revenue still grows 3.4×.
- Rank 2 of 5
- 2025 share 20%
- By 2034 24%
- Revenue $13.60B → $46.63B
USD 13.6 billion of 2025 revenue is generated in Europe, 20% of the global cannabis market rising to USD 46.63 billion in 2034. That makes it the second-largest region covered, in 2025 and again in 2034.
Share climbs to 24% by 2034, because it outgrows the market's 12.18%; the revenue added here is disproportionate to where the region started.
The source mix reported at global level applies here, with Marijuana the largest line at 34% of 2025 revenue and Industrial Hemp the fastest-growing at 15.77%. The full report breaks Europe out along every axis and by country.
Germany
The largest market in Europe, growing 3.7×.
- In region 1 of 2
- Of region 45%
- Of global 9%
- Revenue $6.12B → $22.38B
USD 6.12 billion of Europe's 2025 revenue is generated in Germany, the region's largest market, reaching USD 22.38 billion by 2034. At 45% of the region in 2025 it leads, but a majority of Europe's revenue is generated in other markets. The region itself runs USD 13.6 billion to USD 46.63 billion over the same period, and this is the market carrying the country-level detail in the full report.
The source pattern in Germany is the global one: 34% of 2025 revenue in Marijuana, 31% by 2034, against 15.77% growth in Industrial Hemp taking it from 3% to 4%. With 45% of Europe concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Revenue by source for Germany is reported separately in the full report.
In Germany, cannabis for medical purposes is regulated under the Narcotics Act and overseen by the Federal Institute for Drugs and Medical Devices, requiring cultivation, processing, and distribution to occur under narcotics-handling licences with cannabis dispensed through pharmacies against prescription. Recent reform legalising limited non-commercial cultivation operates through registered growers' associations supervised by regional health authorities, separate from the medical supply chain. Any supplier entering the medical channel must demonstrate Good Manufacturing Practice and Good Distribution Practice conformity, secure import and handling authorisations, and meet pharmacopoeial quality and labelling standards consistent with other prescription medicines, while adult-use associations operate under strict non-commercial, membership-based cultivation limits rather than open retail sale.
The suppliers tracked in this study (Canopy Growth Corporation, GW Pharmaceuticals, plc, Aurora Cannabis, Inc., Aphria, Inc., Cronos Group, Tilray, Sundial Growers Inc., Insys Therapeutics, Inc., The Scotts Company LLC, VIVO Cannabis Inc., Cara Therapeutics Inc., Curaleaf Holdings, Inc., Trulieve Cannabis Corp., Green Thumb Industries Inc. and Verano Holdings Corp.) compete in Germany across the source lines above. The commercially relevant division is 34% of 2025 revenue in Marijuana, where the volume is, against 15.77% growth in Industrial Hemp, where share moves.
United Kingdom
2nd-largest in Europe, growing 3.2×.
- In region 2 of 2
- Of region 28%
- Of global 5.6%
- Revenue $3.81B → $12.12B
Within Europe, the United Kingdom accounts for 28% of regional revenue and 5.6% of the global total, worth USD 3.81 billion in 2025 and USD 12.12 billion by 2034.
Asia Pacific Market Analysis
The 3rd-largest region covered — it picks up 3 points of share by 2034, while revenue still grows 3.8×.
- Rank 3 of 5
- 2025 share 9%
- By 2034 12%
- Revenue $6.12B → $23.32B
In Asia Pacific, 9% of global revenue puts 2025 at USD 6.12 billion with USD 23.32 billion projected for 2034. That makes it the third-largest region covered, in 2025 and again in 2034.
By 2034 the share has moved up to 12%, because it outgrows the market's 12.18%; the revenue added here is disproportionate to where the region started.
Segment composition follows the global pattern: Marijuana largest at 34% of 2025 revenue, Industrial Hemp fastest at 15.77%. The full report breaks Asia Pacific out along every axis and by country.
Thailand
The largest market in Asia Pacific, growing 3.5×.
- In region 1 of 2
- Of region 35%
- Of global 3.1%
- Revenue $2.14B → $7.46B
35% of Asia Pacific's base-year revenue comes from Thailand; USD 2.14 billion, rising to USD 7.46 billion by 2034. 35% of the region in the base year makes it the largest market here without making it the region. Set against USD 6.12 billion and USD 23.32 billion for the region, it is why this market rather than a smaller one is the one reported in full.
Demand in Thailand follows the source mix reported at global level: Marijuana is the largest line at 34% of 2025 revenue, moving to 31% by 2034, while Industrial Hemp grows fastest at 15.77% and takes its share from 3% to 4%. Since 35% of Asia Pacific's revenue is generated here, the regional numbers inherit this market's mix rather than smoothing it out. Per-source revenue for Thailand appears on its own in the full report.
In Thailand, cannabis cultivation, processing, and sale are overseen by the Ministry of Public Health together with the Thai Food and Drug Administration, following the removal of cannabis and hemp parts from the country's narcotics list, while extracts exceeding a defined psychoactive compound threshold remain classified as a controlled narcotic. Suppliers must obtain cultivation and processing licences, register premises, and meet Ministry of Public Health standards covering cultivation practice, product testing, and consumer-facing labelling that discloses composition and intended use. Products intended for food, cosmetic, or herbal-medicine channels additionally require conformity with the relevant Thai FDA product category rules, and export or cross-border movement remains subject to narcotics-control permitting administered through national and international drug-control cooperation.
The suppliers tracked in this study (Canopy Growth Corporation, GW Pharmaceuticals, plc, Aurora Cannabis, Inc., Aphria, Inc., Cronos Group, Tilray, Sundial Growers Inc., Insys Therapeutics, Inc., The Scotts Company LLC, VIVO Cannabis Inc., Cara Therapeutics Inc., Curaleaf Holdings, Inc., Trulieve Cannabis Corp., Green Thumb Industries Inc. and Verano Holdings Corp.) compete in Thailand across the source lines above. Two different problems sit on the same axis: holding Marijuana at 34% of 2025 revenue, and taking Industrial Hemp while it grows at 15.77%.
Australia
2nd-largest in Asia Pacific, growing 4.2×.
- In region 2 of 2
- Of region 30.1%
- Of global 2.7%
- Revenue $1.84B → $7.70B
Australia is sized at USD 1.84 billion in 2025, rising to USD 7.7 billion by 2034; 2.71% of global revenue and 30.1% of Asia Pacific. It is reported separately from Thailand across every segmentation axis in the full report.
Latin America Market Analysis
The 4th-largest region covered, holding its share flat through 2034, while revenue still grows 2.9×.
- Rank 4 of 5
- 2025 share 6%
- By 2034 6%
- Revenue $4.08B → $11.66B
6% of the global cannabis market sits in Latin America in 2025, worth USD 4.08 billion and reaches USD 11.66 billion by 2034. Among the five regions it ranks fourth by revenue in both years.
6% of global revenue sits here in 2034, below the 2025 level, while nothing contracts here; other regions simply grow faster, which shows up as relative weight rather than as falling revenue.
Within the region the source split tracks the global one; 34% of 2025 revenue in Marijuana, fastest growth of 15.77% in Industrial Hemp. Latin America is reported axis by axis and country by country in the full study.
Colombia
The largest market in Latin America, growing 3.1×.
- In region 1 of 2
- Of region 40%
- Of global 2.4%
- Revenue $1.63B → $5.13B
The largest single market in Latin America is Colombia, at USD 1.63 billion in 2025 and USD 5.13 billion in 2034. Its 40% of base-year regional revenue leads the region, though enough sits elsewhere that Latin America is not a proxy for it. Regional revenue of USD 4.08 billion in 2025 and USD 11.66 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.
Colombia buys along the same lines as the market globally; Marijuana first at 34% of 2025 revenue and 31% in 2034, Industrial Hemp fastest at 15.77% on a share moving from 3% to 4%. Because the country carries 40% of Latin America, a movement in its own mix shows up in the regional totals rather than being averaged away by neighbouring markets. Revenue by source for Colombia is reported separately in the full report.
Colombia regulates cannabis cultivation and production through licences issued by the Ministry of Justice and Law, covering seed, non-psychoactive, and psychoactive cannabis separately, with the National Narcotics Fund overseeing controlled-substance quotas and chain-of-custody for higher-potency material. Cannabis destined for pharmaceutical or medicinal use additionally falls under the National Institute for Food and Drug Surveillance, which governs manufacturing quality, product registration, and labelling for finished medicines and extracts, while the Ministry of Health sets clinical and prescribing conditions for medical access. Suppliers must secure the applicable cultivation, manufacturing, and export licences, meet good agricultural and manufacturing practice standards, and comply with strict tracking of plant material from cultivation through to processed product.
Canopy Growth Corporation, GW Pharmaceuticals, plc, Aurora Cannabis, Inc., Aphria, Inc., Cronos Group, Tilray, Sundial Growers Inc., Insys Therapeutics, Inc., The Scotts Company LLC, VIVO Cannabis Inc., Cara Therapeutics Inc., Curaleaf Holdings, Inc., Trulieve Cannabis Corp., Green Thumb Industries Inc. and Verano Holdings Corp. are the suppliers covered in Colombia. Volume sits in Marijuana at 34% of 2025 revenue; movement sits in Industrial Hemp at 15.77% growth.
Uruguay
2nd-largest in Latin America, growing 2.7×.
- In region 2 of 2
- Of region 25%
- Of global 1.5%
- Revenue $1.02B → $2.80B
1.5% of global revenue is generated in Uruguay; USD 1.02 billion in 2025, reaching USD 2.8 billion in 2034, and 25% of Latin America.
Middle East and Africa Market Analysis
The 5th-largest region covered, holding its share flat through 2034, while revenue still grows 2.9×.
- Rank 5 of 5
- 2025 share 3%
- By 2034 3%
- Revenue $2.04B → $5.83B
USD 2.04 billion of 2025 revenue is generated in Middle East and Africa, 3% of the global cannabis market rising to USD 5.83 billion in 2034. By revenue it sits fifth across the study, and the ranking does not change between 2025 and 2034.
Its share moves to 3% by 2034, though revenue still rises throughout; what changes is the region's weight against faster-growing ones, which is not the same as weakening demand.
Marijuana leads here as it does globally, at 34% of 2025 revenue, and Industrial Hemp again grows fastest at 15.77%. Middle East and Africa is reported axis by axis and country by country in the full study.
Israel
The largest market in Middle East and Africa, growing 2.7×.
- In region 1 of 2
- Of region 45.1%
- Of global 1.4%
- Revenue $0.92B → $2.51B
45.1% of Middle East and Africa's base-year revenue comes from Israel; USD 0.92 billion, rising to USD 2.51 billion by 2034. It accounts for 45.1% of regional revenue in the base year, the largest single share without dominating the region outright. Set against USD 2.04 billion and USD 5.83 billion for the region, it is why this market rather than a smaller one is the one reported in full.
Israel buys along the same lines as the market globally; Marijuana first at 34% of 2025 revenue and 31% in 2034, Industrial Hemp fastest at 15.77% on a share moving from 3% to 4%. Since 45.1% of Middle East and Africa's revenue is generated here, the regional numbers inherit this market's mix rather than smoothing it out. Per-source revenue for Israel appears on its own in the full report.
In Israel, medical cannabis is regulated by the Ministry of Health through its Medical Cannabis Unit, which licenses cultivators, processors, and distributors and sets standards aligned with Good Agricultural and Collection Practice and Good Manufacturing Practice for finished products. Patients access cannabis only through a physician's authorisation and licensed pharmacies or distribution points, with suppliers required to meet strict quality, testing, and traceability requirements covering contaminants, cannabinoid composition, and batch consistency. Labelling must identify strain, composition, and handling instructions in a form approved by the regulator, and any export of medical cannabis is additionally subject to separate Ministry of Health export licensing and international narcotics-control obligations, keeping the supply chain tightly closed relative to adult-use or unregulated markets.
The suppliers tracked in this study (Canopy Growth Corporation, GW Pharmaceuticals, plc, Aurora Cannabis, Inc., Aphria, Inc., Cronos Group, Tilray, Sundial Growers Inc., Insys Therapeutics, Inc., The Scotts Company LLC, VIVO Cannabis Inc., Cara Therapeutics Inc., Curaleaf Holdings, Inc., Trulieve Cannabis Corp., Green Thumb Industries Inc. and Verano Holdings Corp.) compete in Israel across the source lines above. The commercially relevant division is 34% of 2025 revenue in Marijuana, where the volume is, against 15.77% growth in Industrial Hemp, where share moves.
South Africa
2nd-largest in Middle East and Africa, growing 3.1×.
- In region 2 of 2
- Of region 25%
- Of global 0.8%
- Revenue $0.51B → $1.57B
South Africa is sized at USD 0.51 billion in 2025, rising to USD 1.57 billion by 2034; 0.75% of global revenue and 25% of Middle East and Africa. It is reported separately from Israel across every segmentation axis in the full report.
Request this sample to see the full data tables and segment-level detail behind this analysis.
Report Coverage
This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by Source, Derivative, End-Use, Depression and Anxiety, Distribution Channel, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.
Competitive Landscape
Scale in Marijuana and Growth in Industrial Hemp Set the Terms of Competition
The suppliers covered are: Canopy Growth Corporation, GW Pharmaceuticals, plc, Aurora Cannabis, Inc., Aphria, Inc., Cronos Group, Tilray, Sundial Growers Inc., Insys Therapeutics, Inc., The Scotts Company LLC, VIVO Cannabis Inc., Cara Therapeutics Inc., Curaleaf Holdings, Inc., Trulieve Cannabis Corp., Green Thumb Industries Inc. and Verano Holdings Corp..
Where suppliers actually compete is along the source axis. The largest block of revenue is Marijuana: USD 23.12 billion in 2025 at 34% of the total, 31% in 2034. Incumbency there is expensive to challenge. Share moves in Industrial Hemp, growing 15.77% against 10.35% for Flowers. The two rarely sit with the same supplier, and that is the reason a USD 68 billion market is not already consolidated.
Competitive position rests on cultivation scale and yield consistency, since licensed growing capacity is capital-intensive and slow to expand once a market opens. Regulatory and licensing experience matters nearly as much: operators who have already cleared one jurisdiction's approval process move faster into the next. Distribution reach through owned dispensaries or pharmacy and retail partnerships determines who reaches the shopper first, while brand recognition carries more weight in adult-use categories than in medical ones. Smaller and regional operators compete on cultivar specialization, faster local licensing and tighter service in single-market territories rather than matching the largest producers on volume.
Presence matters unevenly by region. With 62% of 2025 revenue in North America and 20% in Europe, a supplier's coverage of those two decides most of its addressable base before any product question arises.
The full report carries a profile, financials, share and development history for each company named; none of that is in this summary.
List of Key Cannabis Market Companies Profiled
15 companies profiled. Company profiles, including financials, product portfolios and recent developments, are part of the full report.
- Canopy Growth Corporation(Canada)
- GW Pharmaceuticals, plc(United Kingdom)
- Aurora Cannabis, Inc.(Canada)
- Aphria, Inc.(Canada)
- Cronos Group(Canada)
- Tilray(Canada)
- Sundial Growers Inc.(Canada)
- Insys Therapeutics, Inc.(United States)
- The Scotts Company LLC(United States)
- VIVO Cannabis Inc.(Canada)
- Cara Therapeutics Inc.(United States)
- Curaleaf Holdings, Inc.(United States)
- Trulieve Cannabis Corp.(United States)
- Green Thumb Industries Inc.(United States)
- Verano Holdings Corp.(United States)
Geographic Coverage
Every market below is broken out separately in the report.
North America
3Europe
8Asia Pacific
12Latin America
3Middle East and Africa
4Key Insights
Report Scope
Study parameters & segmentationThis study covers market size and forecasts over the 2020–2034 period, segmentation across 5 axes (Source, Derivative, End-use, Depression and Anxiety, Distribution Channel), regional analysis for 5 regions and their constituent countries, a competitive landscape profiling 15 key companies, and the research methodology behind every estimate.
Segmentation
5 axes + regionFull chapter-and-section structure of the report. Segment, region, and company breakdowns are listed as scope. The underlying figures are in the sample and full report.
Table of Contents+−
Chapter 1.Executive Summary
Chapter 2.Premium Insights
Chapter 3.Market Definition
Chapter 4.Research Methodology
Chapter 5.Strategic Imperatives & Market Outlook
Chapter 6.Go-to-Market (GTM) Strategies
Chapter 7.Market Trends, Strategy & Dynamics
Chapter 8.Porter's Five Forces
Chapter 9.PESTEL Analysis
Chapter 10.Value Chain Analysis
Chapter 11.Supply Chain Analysis
Chapter 12.Macro-Economic Factors
Chapter 13.Market Cost Analysis
Chapter 14.Market Supply-Side Analysis
Chapter 15.Global Cannabis Market Size & Projections, 2020–2034, Revenue (USD Billion)
Chapter 16.Global Cannabis Market Overview, By Source, 2020–2034, Revenue (USD Billion)
Chapter 17.Global Cannabis Market Overview, By Derivative, 2020–2034, Revenue (USD Billion)
Chapter 18.Global Cannabis Market Overview, By End-use, 2020–2034, Revenue (USD Billion)
Chapter 19.Global Cannabis Market Overview, By Depression and Anxiety, 2020–2034, Revenue (USD Billion)
Chapter 20.Global Cannabis Market Overview, By Distribution Channel, 2020–2034, Revenue (USD Billion)
Chapter 21.Global Cannabis Market Size — Segment Comparison
Chapter 22.Global Cannabis Geography Overview, 2020–2034, Revenue (USD Billion)
Chapter 23.North America Cannabis Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 24.Europe Cannabis Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 25.Asia Pacific Cannabis Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 26.Latin America Cannabis Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 27.Middle East and Africa Cannabis Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 28.Application / Use-Case Analysis
Chapter 29.Vendor Capability Scorecard
Chapter 30.Scenario Forecasts
Chapter 31.Top 10 Key Clients of Top 10 Players
Chapter 32.Top 10 Suppliers
Chapter 33.Competitive Landscape
Chapter 34.Partnerships & M&A
Chapter 35.Key Vendor Analysis
Chapter 36.Marketing Strategy Analysis, Distributors & Traders
Chapter 37.Outlook of the Market
Chapter 38.Concluding Analyst Note
List of Figures+−
Structural index generated from this report's own section headings, not verified against the delivered report's actual figure numbering.
List of Tables+−
Structural index generated from this report's own section headings, not verified against the delivered report's actual table numbering.
Segmentation Analysis
5 axesBy Source
7- 01Marijuana
- 02Flowers
- 03Oil and Tinctures
- 04Hemp
- 05Hemp CBD
- 06Supplements
- 07Industrial Hemp
By Derivative
3- 01THC
- 02CBD
- 03Others
By End-use
3- 01Medical Use
- 02Cancer
- 03Chronic Pain
By Depression and Anxiety
14- 01Recreational Use
- 02Industrial Use
- 03Epilepsy
- 04Multiple Sclerosis
- 05Arthritis
- 06Post-Traumatic Stress Disorder (PTSD)
- 07Migraines
- 08Glaucoma
- 09Parkinson's
- 10Diabetes
- 11Alzheimer's
- 12AIDS
- 13Amyotrophic Lateral Sclerosis
- 14Tourette's
By Distribution Channel
3- 01Dispensaries and Retail Stores
- 02Pharmacies
- 03Online and E-commerce
Segment categories shown for scope reference. See the Summary tab for revenue share by By Source. Full segment-by-segment detail across every axis is available in the sample and full report.
Research approach
A market size is a claim about the world, and a claim is only as good as the route to it. Every study is built upward from units and prices — what is actually produced, sold or performed, at what it actually changes hands for — rather than from a headline figure divided downwards. Disclosed company revenue is then used to check that build, not to produce it.
The estimate is built upward from licensed cultivation and processing volumes, metric tons of flower-equivalent output, liters of oil and tincture extract, and finished-unit counts for edibles and topicals, multiplied by realized wholesale and retail per-gram or per-unit pricing recorded in each legal jurisdiction. That build is then checked against disclosed revenue from licensed producers and multi-state operators reporting quarterly cultivation and retail sales. Where the two diverge, for example when a licensed producer's reported revenue implies a materially higher realized price than state-tracked wholesale data supports, the bottom-up price or yield assumption for that jurisdiction is corrected rather than the two figures being averaged together.
The four stages
The same sequence runs behind every published study, whatever the industry. The order matters as much as the steps: the segment axes are fixed before any number is collected, so the model is never reshaped to fit whatever data happens to turn up.
What the build rests on, and what checks it
The two are not interchangeable. The left column produces the number; the right column tests it. When the check disagrees with the build, the answer is to find which bottom-up assumption is wrong — a unit count, a price, a take-up rate — not to split the difference between them.
- Volume actually transacted — units produced, installed, dispensed or procedures performed, counted at the level each is genuinely recorded
- Realised pricing by tier and channel, rather than one blended average applied across the whole market
- Take-up and frequency: how much of the addressable base buys, and how often it repeats
- Disclosed revenue of the companies serving the market, where filings separate it far enough to be usable
- Buyer-side spending totals — capital budgets, procurement lines, or the output of the end market the product is bought against
- Trade and customs flows, where the product crosses borders in a separately recorded form
Data sources
Published data establishes what happened. Only the people transacting in a market can say why, and what is about to change — so the two are collected separately and weighted differently.
- Commercial and product leadership at the companies that supply the market
- Procurement and specification leads at the organisations that buy it
- Distributors, integrators and channel partners, where the market is served indirectly
- Regulatory and standards specialists, where approval governs what can be sold at all
- Company filings, annual reports and investor disclosure
- Government statistics, customs records and regulatory registers
- Trade association output and standards-body publications
- Technical and peer-reviewed literature, where the market rests on a clinical or engineering claim
Interview targets are concentrated among cultivation and processing operators, dispensary and pharmacy buyers, and state or national cannabis regulators who set licensing caps and track seed-to-sale volumes. Procurement and category managers at multi-state operators and licensed producers provide realized wholesale pricing and product-mix detail that public filings do not break out by state or product form. Sampling weights North America, where the largest number of mature, reporting-obligated licensees operate, alongside Germany and other European medical-cannabis markets moving through active licensing expansion, since regulatory timelines in those markets are shifting quickly enough that desk research alone would lag the current framework.
Desk research draws on state and provincial cannabis regulator seed-to-sale tracking systems, Health Canada's Cannabis Tracking and Licensing System disclosures, the U.S. Census Bureau's hemp and cannabis-adjacent trade data, and the harmonized customs codes used to track cross-border hemp and CBD shipments. Publicly listed producers' quarterly filings and investor disclosures supply company-level revenue and cultivation-capacity figures, and national medical-cannabis patient registries in markets such as Germany and Australia provide prescribing-volume benchmarks against which the medical-use segmentation is checked.
Desk research runs across proprietary research databases including Factiva, OneSource and Hoovers alongside the public sources above. Modelling and statistical validation are run in SAS and SPSS.
Forecasting
The forecast is not a growth rate applied to a base year. It is built from the drivers that are expected to change, each one stated so a reader can disagree with it.
The forecast is built from the pace of new jurisdiction legalization already scheduled or under active legislative review, the rate at which existing medical programs convert into adult-use frameworks, and the price trajectory observed in mature markets as cultivation capacity catches up with early-stage scarcity pricing. It normalizes for the sharp price declines recorded in the first one to two years after a new market opens, treating that compression as a one-time adjustment rather than a trend that continues indefinitely. For the forecast to hold, no major legal market can reverse course through re-criminalization, and federal-level banking and interstate-commerce restrictions in the United States are assumed to ease gradually rather than remain fixed.
Triangulation and validation
No figure enters a report on the strength of one source. Where the two sizing routes disagree the difference is not averaged away — the assumption causing it is isolated, tested against a third independent measure, and either corrected or carried forward as a stated limitation. Historical years are back-tested against the growth actually recorded before any forecast is allowed to run forward from them.
Outputs are back-tested against recorded year-over-year growth in the markets that legalized earliest, Canada's federal adult-use program and the first-wave U.S. states, to confirm the modeled adoption curve matches what those markets actually produced. Segment-share shifts, particularly the move from flower toward oil, tincture and CBD-wellness formats, were reviewed against category-level retail sales data rather than assumed to continue in a straight line. Sensitivities were tested around the pace of U.S. federal reform and around per-unit price trajectories in markets approaching cultivation oversupply, since both are the assumptions most likely to move the forecast if they resolve differently than modeled.
Confidence and limitations
Where an estimate is firm and where it is not is stated rather than left to be inferred from the precision of the number.
Confidence is firmest in North America and in flower, oil and tincture product forms, where licensed-producer disclosures and state seed-to-sale data give a direct read on volume and price. It is thinner in condition-specific medical estimates, such as epilepsy or multiple sclerosis, where patient-level prescribing data is not consistently published, and in newer Asia-Pacific medical markets where reporting infrastructure is still forming. A structural risk that would force a revision is any reversal of federal-level tolerance in a major market; a smaller one is faster-than-modeled price compression as cultivation capacity continues to outpace near-term demand.
Every report purchase includes direct access to the lead analyst for scoping questions on the data, at no extra cost and with no separate booking process.
Request a tailored breakdown by geography, segment, or competitor set beyond what's in the standard report.
Questions This Report Answers
6 questionsWhat is the market size and growth rate, globally and by region?
How is the market segmented, and which segments lead?
Which regions and countries are covered, and how do they compare?
What are the key drivers, restraints, opportunities and challenges?
Who are the leading companies operating in this market?
What trends are expected to shape the market through the forecast period?
Frequently Asked Questions
01What is the Cannabis Market projected to reach?
USD 194.3 Billion by 2034, CAGR 12.18%
02What years does this report cover?
Study period 2020–2034, base year 2025, historical data 2020-2024, forecast period 2026-2034.
03Which regions are covered?
North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
04Which region accounted for the largest market share?
North America leads with 62% of global revenue through 2034.
05Which segment leads the market?
Marijuana is the largest line by Source, at 34% of revenue in 2025.
06Who are the key companies profiled?
Canopy Growth Corporation, GW Pharmaceuticals, plc, Aurora Cannabis, Inc., Aphria, Inc., Cronos Group, Tilray, Sundial Growers Inc., Insys Therapeutics, Inc., The Scotts Company LLC, VIVO Cannabis Inc., Cara Therapeutics Inc., Curaleaf Holdings, Inc., Trulieve Cannabis Corp., Green Thumb Industries Inc., Verano Holdings Corp.. Full profiles are part of the paid report.
07Can the segmentation be customized?
Yes. Custom data cuts by geography, segment, or competitor set are available on request.
Why choose CDI
Need this report shaped around your question?
The scope isn't fixed. Tell us what your team needs that the standard edition doesn't cover, and an analyst will come back on what can be adjusted and how long it takes, before you commit to anything.
Most licences include 30–60 hours of customization at no extra cost. See what each licence includes
Additional Companies
Add competitors, suppliers or the peer set you benchmark against to the companies already covered.
Deeper Competitive View
Sharpen the landscape work around your own position: product line, channel, or a named shortlist of rivals.
Extra Segment Splits
Break the market down along an axis the standard scope doesn't cut it by, or go a level deeper inside one.
Application Focus
Narrow the analysis to the specific use cases and end users your team actually sells into.
Different Time Frame
Move the base year, or widen the historical and forecast windows the study is built on.
Country-Level Detail
Go below region level into the individual countries that matter to you, rather than the standard geography split.